<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01885156</url>
  </required_header>
  <id_info>
    <org_study_id>MUS 90200_3028_1</org_study_id>
    <nct_id>NCT01885156</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris</brief_title>
  <official_title>A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To see how well Naftin 1% cream works when applied once daily to the affected area. The
      results will be compared to those using a placebo cream, which is a cream with no active
      ingredient. Safety will also be measured.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).</measure>
    <time_frame>Week 6</time_frame>
    <description>- Summarization of AEs (local and systemic)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH and culture positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).</measure>
    <time_frame>Week 6</time_frame>
    <description>Complete Cure based on:
-Negative mycology results; absence (Grade 0) of erythema, scaling, and pruritis
Other efficacy variables assessed at Week 2, Week 4, and Week 6:
Effective treatment
Mycological cure
Clinical Success
Clinical Cure
Investigator Global Assessment
Subject Satisfaction Assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Tinea Cruris</condition>
  <condition>Jock Itch</condition>
  <arm_group>
    <arm_group_label>Placebo Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topically applied once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naftin 1% Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topically applied once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftin 1% Cream</intervention_name>
    <description>Topically applied once a day</description>
    <arm_group_label>Naftin 1% Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Cream</intervention_name>
    <description>Topically applied once a day</description>
    <arm_group_label>Placebo Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Review and sign statement of Informed Consent and HIPAA authorization.

          -  Males or non-pregnant females ≥ 12 years of age to 17 years, 11 months, of any race or
             sex. Females of child-bearing potential must have a negative urine pregnancy test.

          -  The parent/legal guardian must complete the informed consent process AND the subject
             must complete the assent process and sign the appropriate form (if age appropriate).

          -  Presence of tinea cruris characterized by clinical evidence of a tinea infection (at
             least moderate erythema, moderate scaling, and mild pruritus) based on signs and
             symptoms.

          -  KOH positive baseline skin scrapings obtained from the site most severely affected or
             a representative site of the overall severity.

          -  Subjects must be in good health and free from any clinically significant disease that
             might interfere with the study evaluations.

          -  Subject must be able to understand the requirements of the study and willing to comply
             with the study requirements.

        Exclusion Criteria:

          -  A life threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable
             angina, or myocardial infarction) within the last 6 months.

          -  Subjects with abnormal findings - physical or laboratory - that are considered by the
             investigator to be clinically important and indicative of conditions that might
             complicate interpretation of study results.- Severe dermatophytoses, mucocutaneous
             candidiasis, or bacterial skin infection.

          -  Subjects with a known hypersensitivity to study medications or their components.

          -  Subjects who have a recent history or who are currently known to abuse alcohol or
             drugs.

          -  Uncontrolled diabetes mellitus.

          -  Hemodialysis or chronic ambulatory peritoneal dialysis therapy.

          -  Current diagnosis of immunocompromising conditions.

          -  Atopic or contact dermatitis.

          -  Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection.

          -  Female subject who is pregnant or lactating, who is not using or does not agree to use
             an acceptable form of contraception during the study, or who intends to become
             pregnant during the study (females who are surgically sterilized for at least 2 years
             are not considered to be of childbearing potential).

          -  Subjects using the following medications:

               -  Topical anti-fungal therapy, powders or topical corticosteroids applied within 14
                  days prior to randomization. Terbinafine, butenafine, and naftifine (topical)
                  within 30 days prior to randomization.

               -  Oral anti-fungal therapies within 3 months of randomization (8 months for oral
                  terbinafine).

               -  Systemic antibiotic or corticosteroid treatment within 30 days of randomization.

               -  Any other significant treatments, except hormonal contraception and multivitamin,
                  at the discretion of the investigator that would interfere with study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Plaum, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merz North America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Merz Investigational Site # 501001</name>
      <address>
        <city>Belize City</city>
        <country>Belize</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site # 501002</name>
      <address>
        <city>Belize City</city>
        <country>Belize</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site # 180002</name>
      <address>
        <city>San Cristobal</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site # 180001</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site # 504001</name>
      <address>
        <city>San Pedro Sula</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belize</country>
    <country>Dominican Republic</country>
    <country>Honduras</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2013</study_first_submitted>
  <study_first_submitted_qc>June 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <disposition_first_submitted>March 26, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 26, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 15, 2015</disposition_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naftifine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

